

Mamiko Odoko,* Natsuko
Tsuchida and Nobuo OkabeFaculty of Pharmaceutical Sciences, Kinki
University, Kowakae 3-4-1, Higashiosaka,
Osaka 577-8502, JapanCorrespondence e-mail:
odoko@phar.kindai.ac.jp

Key indicators


Single-crystal X-ray study
 $T = 296$ K
Mean $\sigma(\text{C}-\text{C}) = 0.002$ Å
 R factor = 0.018
 wR factor = 0.054
Data-to-parameter ratio = 16.3For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.Aqua{2,2'-[propane-1,3-diylbis(nitrilo-
methylidene)]diphenolato}zinc(II)

In the title compound, $[\text{Zn}(\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2)(\text{H}_2\text{O})]$, the Zn^{II} atom has a distorted pentacoordinate square-pyramidal geometry. A mirror plane passes through the Zn^{II} atom, the central C atom of the propyl group and the O atom of the coordinated water molecule. The two planar Schiff base groups make a dihedral angle of $39.49(6)^\circ$. The crystal packing is stabilized by weak intermolecular interactions *via* the coordinated water molecule.

Received 22 February 2006
Accepted 2 March 2006

Comment

To date, it has been reported that Zn^{II} and its complexes exhibit insulinomimetic activity *in vitro* and anti-diabetic effects in animals (Chen *et al.*, 1998; Song *et al.*, 2001; Sakurai *et al.*, 2002). It has also been reported that several vanadium complexes of the tetradentate Schiff base salen-type [N,N' -bis(salicylidene)-1,2-ethylenediamine] ligands show insulin-enhancing properties (Durai & Saminathan, 1997; Correia *et al.*, 2004). As part of a study aimed to design new insulinomimetic Zn^{II} complexes, we have synthesized the title compound, (I), in which bis(N,N' -salicylidene)propane-1,3-diamine (salpr) behaves as a tetradentate Schiff base ligand.



The crystal structure and the atom-numbering scheme of (I) are shown in Fig.1. Selected geometric parameters are shown in Table 1. The Zn^{II} atom is in a pentacoordinate distorted square-pyramidal geometry, defined by two N atoms and two O atoms of the salpr ligand as the basal plane and by one apical O atom of a water molecule. The Zn^{II} atom sits in the body of the pyramid $0.3539(7)$ Å from the $\text{O1}/\text{N1}/\text{N1}^i/\text{O1}^i$ basal plane [symmetry code: (i) $x, \frac{1}{2} - y, z$]. A mirror plane passes through the Zn^{II} atom, the central C9 atom of the propyl group and the O2 atom of the coordinated water molecule. The two planar Schiff base groups (r.m.s. deviation of fitted atoms of $\text{O1}/\text{C1}-\text{C6}/\text{C7}/\text{N1}$ and $\text{O1}^i/\text{C1}^i-\text{C6}^i/\text{C7}^i/\text{N1}^i = 0.0207$ Å) make a dihedral angle of $39.49(6)^\circ$. The six-membered chelate ring composed of Zn^{II} and the propane-diamine group has a chair conformation with out-of-plane Zn^{II} and C9 atoms.

In the crystal structure, complex molecules are weakly linked with one another along the *a* axis *via* the coordinated

water molecules. The water molecule makes bifurcated O—H···O hydrogen bonds with two O atoms of a neighboring salpr ligand. Atom C8 of the propyl group makes another C—H···O contact with O2 of the water molecule of a neighboring complex (Fig. 2 and Table 2).

Experimental

N,N'-Bis(salicylidene)propane-1,3-diamine (5 mg) was dissolved in 80% (v/v) EtOH–water (5 ml) and zinc chloride (1.2 mg) dissolved in a small amount of water was added at room temperature. Colorless platelet-shaped crystals appeared from this mixture after a few days by evaporation at room temperature.

Crystal data

[Zn(C₁₇H₁₆N₂O₂)(H₂O)]

M_r = 363.72

Orthorhombic, *Pnma*

a = 8.731 (7) Å

b = 24.06 (2) Å

c = 7.488 (7) Å

V = 1573 (2) Å³

Z = 4

D_x = 1.536 Mg m⁻³

Mo *K*α radiation

Cell parameters from 13198

reflections

θ = 3.4–27.5°

μ = 1.58 mm⁻¹

T = 296.1 K

Platelet, colorless

0.20 × 0.20 × 0.10 mm

Data collection

Rigaku R-AXIS RAPID
diffractometer

ω scans

Absorption correction: multi-scan

(*ABSCOR*; Higashi, 1995)

T_{min} = 0.668, *T_{max}* = 0.854

15638 measured reflections

1845 independent reflections

1579 reflections with $F^2 > 2\sigma(F^2)$

R_{int} = 0.016

θ_{max} = 27.5°

h = -11 → 11

k = -31 → 31

l = -9 → 9

Refinement

Refinement on *F*²

$R[F^2 > 2\sigma(F^2)] = 0.018$

$wR(F^2) = 0.054$

S = 1.10

1845 reflections

113 parameters

H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0353P)^2$

+ 0.1946*P*]

where $P = (F_o^2 + 2F_c^2)/3$

(Δ/σ)_{max} = 0.001

$\Delta\rho_{\text{max}} = 0.37 \text{ e } \text{Å}^{-3}$

$\Delta\rho_{\text{min}} = -0.25 \text{ e } \text{Å}^{-3}$

Table 1

Selected geometric parameters (Å, °).

Zn1—O1	2.027 (2)	Zn1—N1	2.112 (2)
Zn1—O2	2.012 (1)		
O1—Zn1—O1 ⁱ	86.05 (3)	O2—Zn1—N1	99.70 (3)
O1—Zn1—O2	100.00 (3)	N1—Zn1—N1 ⁱ	94.06 (4)
O1—Zn1—N1	86.59 (3)		

Symmetry code: (i) $x, -y + \frac{1}{2}, z$.

Table 2

Hydrogen-bond geometry (Å, °).

<i>D</i> —H··· <i>A</i>	<i>D</i> —H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> —H··· <i>A</i>
O2—H2w···O1 ⁱⁱⁱ	0.88	1.77	2.590 (3)	154
C8—H8b···O2 ⁱⁱⁱ	0.97	2.63	3.407 (2)	137

Symmetry codes: (ii) $x - \frac{1}{2}, y, -z + \frac{3}{2}$; (iii) $x - \frac{1}{2}, -y + \frac{1}{2}, -z + \frac{3}{2}$.

All H atoms, except for those of the water molecule, were located in difference Fourier maps and were placed at ideal positions and




Figure 1

The molecular structure of (I), showing the atom-numbering scheme. Displacement ellipsoids are shown at the 50% probability level and H atoms are shown as spheres of arbitrary radii. Unlabeled atoms are related to labeled atoms by the symmetry operation $x, \frac{1}{2} - y, z$.




Figure 2

A view of the crystal packing of (I). Dashed lines indicate hydrogen bonds and intermolecular contacts.

treated as riding [C—H = 0.93 Å and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ for aromatic H atoms; C—H = 0.97 Å and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ for methylene H atoms]. H atoms of the water molecule were located in difference Fourier maps and treated as riding [$U_{\text{iso}}(\text{H}) = 1.5U_{\text{eq}}(\text{O})$].

Data collection: *RAPID-AUTO* (Rigaku, 1998); cell refinement: *RAPID-AUTO*; data reduction: *CrystalStructure* (Rigaku/MS, 2005) and *CRYSTALS* (Betteridge *et al.*, 2003); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3* (Farrugia, 1997); software used to prepare material for publication: *CrystalStructure*.

References

- Altomare, A., Burla, M. C., Camalli, M., Cascarano, G., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.
- Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, C. K. & Watkin, D. J. (2003). *J. Appl. Cryst.* **36**, 1487.
- Chen, M. D., Liou, S. J., Lin, P. Y., Yang, V. C., Alexander, P. S. & Lin, W. H. (1998). *Biol. Trace Elem. Res.* **61**, 303–311.
- Correia, I., Pessoa, J. C., Duarte, M. T., Henriques, R. T., Piedade, M. F. M., Veiros, L. F., Jakusch, T., Kiss, T., Doernyei, A., Castro, M. M. C. A., Geraldes, C. F. G. C. & AVECILLA, F. (2004). *Chem. Eur. J.* **10**, 2301–2317.
- Durai, N. & Saminathan, G. (1997). *J. Clin. Biochem. Nutr.* **22**, 31–39.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
- Rigaku (1998). *RAPID-AUTO*. Rigaku Corporation, 3-9-12 Akishima, Tokyo 196-8666, Japan.
- Rigaku/MS (2005). *CrystalStructure*. Version 3.7. Rigaku/MS, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
- Sakurai, H., Kojima, Y., Yoshikawa, Y., Kawabe, K. & Yasui, H. (2002). *Coord. Chem. Rev.* **226**, 187–198.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Song, M. K., Rosenthal, M. J., Hong, S., Harris, D. M., Hwang, I., Yip, I., Golub, M. S., Ament, M. E. & Go, V. L. W. (2001). *Metab. Clin. Exper.* **50**, 53–59.